Last updated: July 13, 2026 · ← Back to Stock Fact Sheets
NYSE: JNJ
Johnson & Johnson
Pharmaceuticals & MedTech · New Brunswick, NJ · Founded 1886Live price: Yahoo Finance →
Data as of July 13, 2026
Q1 2026 sales
$24.1BReported sales growth
+9.9% YoYAdjusted EPS (Q1)
$2.70GAAP EPS (Q1)
$2.14Innovative Medicine sales
$15.4BFY26 sales guide
$100.8BFY26 adj. EPS guide
$11.55Next earnings
Jul 15, 2026FY2026 sales guidance: initial vs. raised ($B)
FY2026 adjusted EPS guidance: initial vs. raised ($)
Company snapshot
| Market cap | ~$618B |
| 1-year stock performance | +59.6% |
| Consecutive dividend increases | 64 years (Dividend King) |
| Segments | Innovative Medicine, MedTech |
| Darzalex sales (Q1) | $3.96B |
| Carvykti sales (Q1) | $597M (+62% YoY) |
| $1B+ revenue products | 28 platforms/products |
| Next earnings | Jul 15, 2026 (Q2 FY26) |
Leadership & pipeline
| CEO / Chairman | Joaquin Duato |
| STELARA headwind (Q1) | ~920 bps drag |
| Recent approval | ICOTYDE (oral peptide, psoriasis) |
| Recent approval | TECVAYLI + DARZALEX FASPRO combo |
| Recent launch | VARIPULSE Pro (5x faster pulse) |
| Recent launch | TECNIS PureSee IOL (cataract) |
| Enterprise Business Review | Dec 8, 2026 |
Analyst price targets (pre-Q2 earnings)
TD Cowen
$300
Raised from $250
RBC Capital
$287
Raised from $265
Guggenheim
$270
Raised from $266
BofA Securities
$263
Neutral, from $254
Street average
~$269
Buy
↗ Bull case
- Raised FY2026 sales and adjusted EPS guidance following a strong Q1 beat
- Innovative Medicine growing double-digit ex-STELARA headwind; 28 products now generate $1B+ each in annual revenue
- Stock up ~60% over the past year with momentum heading into Q2 print
- Multiple sell-side target hikes ahead of earnings (TD Cowen $300, RBC $287, Guggenheim $270)
- 64th consecutive annual dividend increase — Dividend King status appeals to defensive, income-focused investors
- Diversified across Innovative Medicine and MedTech reduces reliance on any single product
- Active pipeline progress: recent approvals in psoriasis, multiple myeloma, cardiac ablation, and cataract surgery
↘ Bear case
- Consensus expects Q2 EPS growth of only roughly 2–3% YoY — a deceleration from Q1’s pace
- STELARA biosimilar competition remains a meaningful (~920 bps) drag on Innovative Medicine growth
- Ongoing talc litigation remains a legal and headline overhang
- Stock already up ~60% over the past year — a lot of good news may already be priced in
- Insider activity has been one-directional recently, with sales but no purchases over the past six months
- Wide analyst target range ($214–$300 across various firms) reflects real disagreement on fair value
- Broader political and regulatory pressure on U.S. drug pricing remains an ongoing risk for the sector
For informational purposes only. Not investment advice. Financials from Q1 2026 earnings (April 14, 2026). Q2 2026 results due July 15, 2026. Price data not shown — check live quote.
Johnson & Johnson (JNJ) — Company Overview
Johnson & Johnson (NYSE: JNJ) is a global healthcare leader operating through two segments — Innovative Medicine and MedTech — spanning oncology, immunology, neuroscience, cardiovascular disease, surgery, and vision care. Headquartered in New Brunswick, New Jersey, and led by Chairman and CEO Joaquin Duato, JNJ has posted a 64th consecutive annual dividend increase, cementing its status as a Dividend King. The stock has rallied roughly 60% over the past year, outpacing both the S&P 500 and the broader healthcare sector as investors reward accelerating pharmaceutical growth and pipeline execution.
Q1 2026 Earnings: Guidance Raised
JNJ reported Q1 2026 results on April 14, 2026. Worldwide sales rose 9.9% to $24.1 billion, with 6.4% operational growth and 5.3% adjusted operational growth. GAAP EPS was $2.14 and adjusted EPS came in at $2.70. Innovative Medicine sales reached $15.4 billion, up 11% (7.4% operationally despite a roughly 920-basis-point drag from STELARA biosimilar competition), with ten brands posting double-digit growth and 28 platforms or products each generating at least $1 billion in annual revenue. Darzalex alone generated $3.96 billion in the quarter, while Carvykti sales surged 62% year-over-year to $597 million. Following the beat, management raised full-year 2026 guidance to an estimated $100.8 billion in reported sales (7.0% at the midpoint) and adjusted EPS of $11.55 (7.1% at the midpoint), both modest increases from the initial guidance issued in January.
Q2 2026 Earnings Preview: July 15
Johnson & Johnson reports Q2 2026 results on Wednesday, July 15, 2026, before market open — one day ahead of UnitedHealth and the broader bank earnings wave. Consensus estimates call for adjusted EPS in the $2.83–$2.86 range (roughly 2–3% growth year-over-year) on revenue near $25.1 billion, up about 5.9%. JNJ has beaten Wall Street’s bottom-line estimate in each of the past four quarters. Investors will be watching for continued momentum in Innovative Medicine ex-STELARA, MedTech performance, and any update on the STELARA biosimilar impact as it continues to roll off.
Analyst Reaction Ahead of Earnings
Sell-side price targets have moved higher into the print. TD Cowen raised its target to $300 from $250, RBC Capital moved to $287 from $265, and Guggenheim lifted its target to $270 from $266, all maintaining bullish ratings. BofA Securities raised its target to $263 from $254 but kept a Neutral rating, illustrating that not every analyst sees further upside from current levels. The Street’s average price target sits in the high-$260s with an overall Buy consensus, though individual targets range as wide as $214 to $300, underscoring real disagreement on how much of the growth story is already reflected in the share price.
Related Coverage on FactSheets.com
This fact sheet is for informational purposes only and does not constitute investment advice. Data as of July 13, 2026.
